Drug Monograph

Veltassa (Patiromer)

patiromer sorbitex calcium

Cation Exchange Resin / Potassium Binder · Oral (powder for suspension)
Pharmacokinetic Profile
Systemic Absorption
Not absorbed
Onset of Action
4–7 hours
Metabolism
None (non-absorbed polymer)
Elimination
Fecal (as intact polymer with bound K+)
Counterion
Calcium-sorbitol
Clinical Information
Drug Class
Cation exchange resin (potassium binder)
Available Doses
1 g, 8.4 g, 16.8 g, 25.2 g packets
Route
Oral (suspension)
Renal Adjustment
None required
Hepatic Adjustment
None required
Pregnancy
No expected fetal risk (not absorbed)
Lactation
Compatible (not absorbed)
Schedule
Prescription only (non-controlled)
Generic Available
No
Rx

Indications for Patiromer

IndicationApproved PopulationTherapy TypeStatus
HyperkalemiaAdultsMonotherapy or adjunct to dietary modificationFDA Approved
HyperkalemiaPediatric patients ≥12 yearsMonotherapy or adjunct to dietary modificationFDA Approved
HyperkalaemiaAdults and adolescents 12–17 yearsMonotherapy or adjunctEMA Approved

Patiromer is a non-absorbed potassium-binding polymer approved for the management of hyperkalemia. It works by exchanging calcium for potassium in the gastrointestinal lumen, thereby increasing fecal potassium excretion and reducing serum potassium levels. The clinical significance of patiromer extends beyond simple potassium correction: by controlling hyperkalemia, it enables continued use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with chronic kidney disease and heart failure who would otherwise require dose reduction or discontinuation of these cardioprotective and renoprotective medications.

Limitation of Use

Patiromer must not be used as emergency treatment for life-threatening hyperkalemia because its onset of action is delayed (4–7 hours). Acute hyperkalemia with ECG changes requires standard emergency interventions including IV calcium, insulin with dextrose, and sodium bicarbonate.

Off-Label Uses

RAASi enablement in heart failure with reduced ejection fraction (HFrEF): The DIAMOND trial (2022) demonstrated that patiromer enables optimisation of guideline-directed MRA and RAASi therapy in patients with HFrEF and current or historical hyperkalemia. While this represents the drug’s most studied off-label application, the FDA indication remains limited to hyperkalemia treatment rather than RAASi enablement per se. Evidence quality: High (phase 3 RCT, n=878).

Spironolactone enablement in resistant hypertension with CKD: The AMBER trial showed that patiromer enabled more patients with resistant hypertension and CKD to remain on spironolactone. Evidence quality: High (phase 2 RCT, n=295).

Dose

Dosing for Patiromer

Adult Dosing

Clinical ScenarioStarting DoseMaintenance DoseMaximum DoseNotes
Chronic hyperkalemia — mild (K+ 5.1–5.5 mEq/L)8.4 g once daily8.4–16.8 g once daily25.2 g/dayTitrate by 8.4 g at ≥1-week intervals based on serum K+
Mix in water; drink immediately
Chronic hyperkalemia — moderate (K+ 5.5–6.5 mEq/L)8.4 g once daily8.4–25.2 g once daily25.2 g/dayFDA label: start 8.4 g for all adults. Clinical trials (OPAL-HK, AMETHYST-DN) used 16.8 g starting dose for K+ ≥5.5
Titrate more aggressively; recheck K+ within 3–7 days
RAASi-associated hyperkalemia in CKD8.4 g once daily8.4–25.2 g once daily25.2 g/dayGoal: maintain K+ in target range while continuing RAASi
No renal dose adjustment needed (FDA PI)
RAASi enablement in HFrEF8.4 g once daily8.4–25.2 g once daily25.2 g/dayDIAMOND trial protocol: patiromer initiated during RAASi uptitration
Reduces MRA dose-reduction events by 38% (DIAMOND)

Pediatric Dosing (≥12 years)

Clinical ScenarioStarting DoseMaintenance DoseMaximum DoseNotes
Hyperkalemia in adolescents ≥12 years4 g once daily4–25.2 g once daily25.2 g/dayTitrate by 4 g at ≥1-week intervals
Based on limited data (n=14); safety profile similar to adults
Clinical Pearl: Preparation and Administration

Patiromer must be prepared as a suspension immediately before use. Empty the packet contents into approximately 80 mL (1/3 cup) of water, stir thoroughly, and drink immediately. The powder will not dissolve — the mixture will appear cloudy. Alternative vehicles include apple sauce, yogurt, or pudding (minimum 45 mL for doses ≤4 g). Never heat the preparation or add it to hot foods or liquids. If the potassium level falls below the desired range, reduce the dose or discontinue. When discontinuing, serum potassium may rise within 2 days.

PK

Pharmacology of Patiromer

Mechanism of Action

Patiromer is a non-absorbed, sodium-free, cation exchange polymer composed of cross-linked fluoroacrylate beads with a calcium-sorbitol counterion. In the gastrointestinal lumen — primarily the distal colon where potassium concentration is highest — patiromer exchanges its calcium counterion for potassium ions. This binding follows a concentration-dependent process: as free potassium in the colonic lumen decreases, more potassium is secreted from the blood into the gut, resulting in a net increase in fecal potassium excretion and a corresponding decline in serum potassium levels. Because the polymer is entirely non-absorbed, it exerts no systemic pharmacological effects, and the calcium released during the exchange process is predominantly excreted in stool rather than absorbed systemically. Phase 1 studies in healthy volunteers demonstrated a dose-dependent increase in fecal potassium excretion with compensatory reductions in urinary potassium excretion.

ADME Profile

ParameterValueClinical Implication
AbsorptionNot absorbed; acts locally in GI tract. Onset of K+ reduction at 4–7 hours post-dose.No systemic bioavailability; cannot be used for acute emergencies due to delayed onset. Can be taken with or without food.
DistributionConfined to GI lumen; no systemic distribution. Primary site of action is distal colon.No protein binding, no volume of distribution, no drug–drug interactions via systemic distribution.
MetabolismNone. Patiromer is an insoluble, chemically inert cross-linked polymer that is not metabolised.No CYP enzyme involvement; no hepatic dose adjustment required.
EliminationFecal excretion as intact polymer with bound potassium. No renal excretion.No renal dose adjustment needed. Safe across all CKD stages including stage 5 (non-dialysis). 93% of clinical trial patients had CKD.
SE

Side Effects of Patiromer

≥10% Very Common

No adverse effect reached ≥10% incidence in pooled clinical trial data. However, constipation reached 11% in the pivotal OPAL-HK trial individually and is listed in the Common tier below with both rates documented.

1–10% Common
Adverse EffectIncidenceClinical Note
Constipation7.2% (pooled); 11% in OPAL-HKMost common AE across all trials; generally mild to moderate and self-limiting during continued treatment. In AMETHYST-DN (52 weeks), rate was 6.3%. Elderly patients (≥65) report higher rates of GI effects.
Hypomagnesemia5.3% (serum Mg <1.4 mg/dL in ~9%)Patiromer binds magnesium in the colon as well as potassium. Monitor serum magnesium and supplement as needed. AMETHYST-DN reported 7.2% over 52 weeks.
Diarrhea4.8%Aggregate term including frequent bowel movements. Usually mild; may be more common during initial titration period.
Hypokalemia (K+ <3.5 mEq/L)4.7%Dose-related; reversible with dose reduction. In OPAL-HK, hypokalemia occurred in 3% of patients. Monitor potassium and adjust dose accordingly.
Nausea2.3%Generally mild and transient. May improve with alternative preparation vehicles (apple sauce, yogurt).
Abdominal discomfort2.0%Aggregate term for abdominal pain (upper, lower) and general discomfort. Usually mild.
Flatulence2.0%Likely related to sorbitol content of the counterion complex (~4 g sorbitol per 8.4 g patiromer).
Serious Serious (regardless of frequency)
Adverse EffectEstimated FrequencyTypical OnsetRequired Action
Hypersensitivity reaction (lip edema)0.3%Variable; any time during treatmentDiscontinue patiromer permanently. Treat per hypersensitivity protocol. The drug is contraindicated on rechallenge.
Severe hypokalemia (K+ <3.0 mEq/L)RareDays to weeks; dose-dependentReduce dose or discontinue. Replete potassium as clinically indicated. Monitor ECG if K+ <3.0 mEq/L.
Severe hypomagnesemia (Mg <1.2 mg/dL)RareWeeks to months of treatmentInitiate magnesium supplementation. Consider dose reduction if persistent. No evidence of patiromer-related cardiac arrhythmias from hypomagnesemia reported in trials.
GI obstruction or impaction (in predisposed patients)Very rareAny time; risk higher with pre-existing GI motility disordersAvoid use in patients with bowel obstruction, severe constipation, or post-operative motility disorders. Discontinue if obstruction suspected.
Discontinuation Discontinuation Rates
Adults (Pooled Clinical Trials)
2.7% due to adverse reactions
Top reasons: GI adverse reactions (vomiting 0.8%, diarrhea 0.6%, constipation)
HF Subgroup (Pooled Analysis)
7% vs 3% without HF
Top reasons: GI intolerance; higher rates in older patients and those with multiple comorbidities
Reason for DiscontinuationIncidenceContext
Vomiting0.8%Most common individual cause of treatment cessation
Diarrhea0.6%Usually occurs during first weeks of therapy
Other GI causes1.3%Includes constipation, abdominal discomfort, nausea
Managing Constipation

Constipation is the most common adverse effect and typically resolves during continued therapy. Encouraging adequate fluid intake, dietary fibre, and physical activity can help. The sorbitol counterion may partially offset constipation in some patients by its osmotic laxative effect. If constipation is severe or persistent, consider stool softeners. Avoid patiromer in patients with pre-existing severe constipation, bowel obstruction, or fecal impaction.

Int

Drug Interactions with Patiromer

Because patiromer is not systemically absorbed, its interaction profile is entirely local and confined to the GI tract. The polymer can bind certain co-administered oral medications in the gut lumen, potentially reducing their bioavailability. Fifty-six drugs were tested in vitro, and twelve showing potential binding were subsequently evaluated in vivo. Of these, only three (ciprofloxacin, levothyroxine, and metformin) showed reduced systemic exposure when taken simultaneously — an effect that was eliminated by separating administration by three hours. Importantly, many commonly co-prescribed medications in the target population (ACE inhibitors, ARBs, MRAs, SGLT2 inhibitors, loop diuretics, warfarin, apixaban, rivaroxaban, amlodipine) do not require dosing separation.

Moderate Ciprofloxacin
MechanismDirect drug binding in GI tract reduces ciprofloxacin absorption
EffectReduced ciprofloxacin systemic exposure when co-administered; interaction eliminated with 3-hour separation
ManagementAdminister ciprofloxacin at least 3 hours before or after patiromer
FDA PI — In Vivo Study
Moderate Levothyroxine
MechanismBinding of levothyroxine by patiromer polymer in the GI tract
EffectDecreased levothyroxine bioavailability; may lead to inadequate thyroid hormone replacement
ManagementSeparate administration by at least 3 hours. Monitor TSH if initiating or adjusting patiromer in patients on thyroid replacement.
FDA PI — In Vivo Study
Moderate Metformin
MechanismDrug binding in GI tract reduces metformin absorption
EffectReduced metformin systemic exposure; potential for suboptimal glycaemic control
ManagementSeparate administration by at least 3 hours. Monitor blood glucose if starting patiromer in diabetic patients on metformin.
FDA PI — In Vivo Study
Moderate Quinidine
MechanismCation binding in GI tract (identified in vitro; EMA recommendation)
EffectPotential reduction in quinidine absorption
ManagementSeparate administration by at least 3 hours (EMA SmPC recommendation)
EMA SmPC
Minor Other Oral Medications (General)
MechanismPotential for non-specific polymer binding in GI tract
EffectTheoretical reduction in absorption of co-administered oral drugs not yet individually tested
ManagementFor oral drugs not specifically tested, separate administration by at least 3 hours as a precautionary measure
FDA PI
No Separation Needed Verified Non-Interacting Drugs
DrugsACE inhibitors (all), ARBs (all), spironolactone, eplerenone, finerenone, furosemide, bumetanide, torsemide, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), warfarin, apixaban, rivaroxaban, amlodipine, verapamil, metoprolol, atorvastatin, digoxin, clopidogrel, lithium, cinacalcet, trimethoprim, amoxicillin, cephalexin, allopurinol, phenytoin, sacubitril, tacrolimus, glipizide, sevelamer
EvidenceNo clinically significant in vitro binding observed; no dosing separation required (FDA PI)
FDA PI — In Vitro/In Vivo Confirmed
Mon

Monitoring for Patiromer

  • Serum Potassium Baseline, then at each dose adjustment; ongoing as clinically indicated
    Routine
    Primary monitoring parameter. Adjust patiromer dose based on K+ level and target range. Potassium may rise within 2 days of discontinuation. After achieving a stable dose, frequency can be guided by clinical context — typically every 1–3 months in stable outpatients.
  • Serum Magnesium Baseline, then periodically during treatment
    Routine
    Patiromer binds magnesium in the colon. Hypomagnesemia occurred in 5.3% of clinical trial patients. Supplement magnesium if levels fall below normal. Consider checking serum Mg alongside K+ at routine follow-ups.
  • Renal Function Baseline, then per CKD monitoring schedule
    Routine
    While patiromer itself does not require renal dose adjustment, the hyperkalemia it treats is often secondary to CKD. eGFR should be monitored per standard CKD guidelines. In the DIAMOND trial, greater K+ lowering was observed in patients with eGFR <45 mL/min/1.73 m².
  • GI Symptoms Each clinic visit
    Routine
    Assess for constipation, diarrhea, and abdominal discomfort. Patients ≥65 years report more GI adverse effects. Discontinue if bowel obstruction or impaction is suspected.
  • RAASi Therapy Status Each dose adjustment
    Trigger-based
    If patiromer is being used to enable RAASi/MRA continuation, reassess the need for patiromer if RAASi doses are reduced or discontinued. Monitor K+ after any RAASi dose changes. Serum K+ may rise rapidly if RAASi is continued after patiromer discontinuation.
  • TSH (if applicable) 6–8 weeks after starting patiromer in patients on levothyroxine
    Trigger-based
    Only required if the patient is taking levothyroxine. Ensure 3-hour dosing separation and confirm thyroid levels are stable after patiromer initiation.
CI

Contraindications & Cautions for Patiromer

Absolute Contraindications

  • Known hypersensitivity to patiromer sorbitex calcium or any component of the formulation. Mild-to-moderate hypersensitivity reactions, including edema of the lips, have been reported in 0.3% of patients (FDA PI).

Relative Contraindications (Specialist Input Recommended)

  • Severe constipation, bowel obstruction, or fecal impaction: Patiromer may be ineffective and may worsen these conditions. The FDA PI recommends avoidance. If clinical necessity mandates use, specialist GI consultation is advised with close monitoring.
  • Abnormal post-operative bowel motility disorders: Reduced GI transit may impair drug efficacy and increase risk of accumulation and obstruction.
  • Hereditary fructose intolerance: Patiromer contains approximately 4 g of sorbitol per 8.4 g dose as part of its counterion complex. Patients with hereditary fructose intolerance should not take this medication (EMA SmPC).

Use with Caution

  • Patients at risk of hypomagnesemia: Concurrent use of other magnesium-depleting agents (loop diuretics, proton pump inhibitors) may compound the risk. Monitor serum magnesium closely and supplement proactively.
  • Elderly patients (≥65 years): 59.8% of patients in clinical trials were ≥65. While no efficacy differences were observed, GI adverse effects were more frequent in this age group.
  • Life-threatening hyperkalemia: Patiromer must not be used as sole therapy for acute, life-threatening hyperkalemia due to its delayed onset (4–7 hours). Standard emergency interventions must be initiated first.
FDA Labeling Limitation Not for Emergency Use in Life-Threatening Hyperkalemia

The FDA label carries a specific limitation of use statement: patiromer should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. This is prominently placed in the Indications section of the label. While not a boxed warning, this limitation is critical for safe prescribing and should be understood by all clinicians who manage acute hyperkalemia. Emergency treatment requires IV calcium gluconate, insulin with glucose, inhaled beta-agonists, and/or sodium bicarbonate as appropriate.

Pt

Patient Counselling for Patiromer

Purpose of Therapy

Patiromer is prescribed to lower elevated potassium levels in the blood. High potassium can be dangerous to the heart and is often caused by kidney disease or by medications that protect the heart and kidneys. By keeping potassium in a safe range, patiromer allows patients to continue taking these protective medications without needing to reduce their dose.

How to Take

Patiromer is taken once daily as a powder mixed into water (or soft foods like apple sauce, yogurt, or pudding). Each dose should be prepared fresh and consumed immediately. The powder will not dissolve — the mixture will appear cloudy, and this is normal. Patients should follow the prescribed low-potassium diet. The medication must never be heated or mixed into hot foods or liquids, and must never be taken in its dry powder form.

Preparation and Timing
Tell patient Empty the entire packet into approximately one-third cup of water, stir well, add more water if desired, and drink immediately. If any powder remains in the glass, add more water, stir, and drink again. Can be taken with or without food. Take other medications at least 3 hours before or after patiromer unless your prescriber advises otherwise.
Call prescriber If you are unable to take the medication as directed, if you notice changes in how your other medications are working, or if you have questions about which medications need to be separated.
Constipation
Tell patient Constipation is the most commonly reported side effect and usually improves with time. Maintain adequate fluid intake, eat fibre-rich foods, and stay active. Over-the-counter stool softeners may be used if needed.
Call prescriber If constipation becomes severe, if you are unable to have a bowel movement for several days, or if you experience significant abdominal pain or bloating.
Low Magnesium
Tell patient This medication can lower magnesium levels in addition to potassium. Your blood levels will be checked regularly. You may be prescribed a magnesium supplement. Symptoms of low magnesium include muscle cramps, tremors, and fatigue.
Call prescriber If you experience muscle cramps, unusual weakness, tremor, irregular heartbeat, or numbness/tingling.
Do Not Stop Without Medical Advice
Tell patient Do not stop taking patiromer without consulting your prescriber, even if you feel well. Potassium levels can rise within two days of stopping. If you are also taking heart or kidney medications, stopping patiromer without reducing those medications may cause a dangerous rise in potassium.
Call prescriber If you miss multiple doses or wish to discontinue for any reason. Blood potassium levels should be rechecked after stopping.
Storage
Tell patient Store packets in the refrigerator (2–8°C / 36–46°F). If stored at room temperature, use within 3 months of removal from the refrigerator. Avoid exposure to excessive heat above 40°C (104°F). Check the expiration date on each packet.
Call prescriber If packets have been exposed to excessive heat or if you have questions about whether stored medication is still usable.
Ref

Sources

Regulatory (PI / SmPC)
  1. Veltassa (patiromer) for oral suspension. Full prescribing information. Vifor Pharma, Inc. Revised October 2023. FDA Label Primary source for all dosing, adverse reaction rates, drug interaction data, and contraindications in this monograph.
  2. Veltassa (patiromer) Summary of Product Characteristics. European Medicines Agency. EMA SmPC EMA-approved product information including adolescent dosing data, sorbitol content, and hereditary fructose intolerance warning.
Key Clinical Trials
  1. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–221. doi:10.1056/NEJMoa1410853 OPAL-HK trial: pivotal phase 3 study demonstrating patiromer efficacy in CKD patients on RAASi. Source of the 11% constipation rate and 60% vs 15% hyperkalemia recurrence data.
  2. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–161. doi:10.1001/jama.2015.7446 52-week dose-ranging study in diabetic kidney disease; source of long-term safety data including 7.2% hypomagnesemia, 6.3% constipation, and 5.6% hypokalemia rates.
  3. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF trial). Eur Heart J. 2011;32(7):820–828. doi:10.1093/eurheartj/ehq502 First placebo-controlled trial of patiromer in heart failure; demonstrated improved spironolactone titration (91% vs 74% achieving 50 mg/day).
  4. Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362–4373. doi:10.1093/eurheartj/ehac401 Largest patiromer RCT (n=878 randomised); demonstrated 37% reduction in hyperkalemia events and 38% reduction in MRA dose-reduction events in HFrEF patients.
  5. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–1550. doi:10.1016/S0140-6736(19)32135-X AMBER trial: patiromer enabled persistent spironolactone use in resistant hypertension with CKD; key evidence for RAASi enablement.
Guidelines
  1. Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1–S115. doi:10.1016/j.kint.2020.06.019 KDIGO guideline proposing potassium binders as a strategy to manage hyperkalemia and enable continued RAASi use in diabetic CKD.
  2. Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document from the Heart Failure Association of the ESC on the use of newer potassium binders. Eur J Heart Fail. 2020;22(9):1495–1506. doi:10.1002/ejhf.1876 HFA-ESC consensus on patiromer and sodium zirconium cyclosilicate for managing hyperkalemia in heart failure patients to enable MRA use.
Pharmacovigilance / Safety
  1. Bushinsky DA, Spiegel DM, Gross C, et al. Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program. Drug Saf. 2021;44(9):965–977. doi:10.1007/s40264-021-01093-1 Four-year post-marketing pharmacovigilance analysis (2016–2019) confirming consistent safety profile with clinical trial data. Source of pooled adverse event rates.
  2. Patiromer. In: Drugs and Lactation Database (LactMed). National Library of Medicine; 2018. LactMed Authoritative reference for lactation safety; confirms no expected risk to breastfed infants due to non-absorption of patiromer.
Pharmacokinetics / Special Populations
  1. Arthur S, Bianchi S, Budden J, et al. Safety and efficacy of patiromer in hyperkalemic patients with CKD: a pooled analysis of three randomized trials. Kidney360. 2022;3(12):2072–2081. doi:10.34067/KID.0001562022 Pooled analysis of AMETHYST-DN, OPAL-HK, and TOURMALINE (n=632) stratified by CKD stage; confirms efficacy across all stages of kidney disease.
  2. Agarwal R, Sinha AD, Hageman K, et al. Hyperkalemia management in older adults with diabetic kidney disease receiving renin-angiotensin-aldosterone system inhibitors: a post hoc analysis of the AMETHYST-DN clinical trial. Kidney Med. 2021;3(4):546–555.e1. doi:10.1016/j.xkme.2021.02.010 Post hoc analysis in patients ≥75 years (n=60) confirming efficacy and tolerability in elderly; 100% had K+ <5.5 at week 52.